Compare Stocks → Do This Today BEFORE Biden Wins in November (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:FIXXNASDAQ:GTHXNASDAQ:PRVBNASDAQ:RTRXNASDAQ:ZIOP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFIXXHomology Medicines$1.18$0.46▼$17.51$978.01M-0.1390,307 shs22,300 shsGTHXG1 Therapeutics$4.77-4.2%$4.07$1.08▼$6.14$249.38M1.711.59 million shs1.39 million shsPRVBProvention Bio$24.98+3.1%$24.58$3.18▼$25.00$2.37B2.472.28 million shs9.12 million shsRTRXTravere Therapeutics$6.30-4.5%$26.56$8.98▼$24.96$321.63M0.67412,277 shs974,626 shsZIOPZIOPHARM Oncology$1.08$0.77▼$5.95$187.12M1.712.01 million shs2.13 million shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFIXXHomology Medicines0.00%0.00%+1,700.00%+4,736.74%+3,333.24%GTHXG1 Therapeutics+16.08%+12.16%+2.05%+9.93%+70.55%PRVBProvention Bio0.00%0.00%0.00%0.00%0.00%RTRXTravere Therapeutics-3.23%+10.00%-3.79%-20.48%-60.19%ZIOPZIOPHARM Oncology0.00%0.00%0.00%0.00%0.00%“Crash Insurance” For Your Retirement (Ad)When it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFIXXHomology Medicines2.3465 of 5 stars3.30.00.04.80.00.80.6GTHXG1 Therapeutics3.7074 of 5 stars3.32.00.03.83.10.80.6PRVBProvention BioN/AN/AN/AN/AN/AN/AN/AN/ARTRXTravere TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AZIOPZIOPHARM OncologyN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFIXXHomology Medicines2.50Moderate Buy$0.75∞ UpsideGTHXG1 Therapeutics2.50Moderate Buy$8.6781.69% UpsidePRVBProvention BioN/AN/AN/AN/ARTRXTravere TherapeuticsN/AN/AN/AN/AZIOPZIOPHARM OncologyN/AN/AN/AN/ACurrent Analyst RatingsLatest ZIOP, GTHX, FIXX, RTRX, and PRVB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2024GTHXG1 TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.005/1/2024GTHXG1 TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.004/12/2024GTHXG1 TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.002/28/2024GTHXG1 TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$4.00 ➝ $5.002/28/2024GTHXG1 TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.002/13/2024GTHXG1 TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$5.00 ➝ $4.002/13/2024GTHXG1 TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.00(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFIXXHomology Medicines$1.16M0.00N/AN/A$1.26 per share0.00GTHXG1 Therapeutics$84.04M2.97N/AN/A$0.68 per share7.01PRVBProvention Bio$12.90M183.54N/AN/A$1.40 per share17.84RTRXTravere Therapeutics$175.34M1.83N/AN/A$5.15 per share1.22ZIOPZIOPHARM OncologyN/AN/AN/AN/A$0.58 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFIXXHomology Medicines-$112.96M-$1.96N/AN/AN/A-4,779.31%-102.52%-74.91%N/AGTHXG1 Therapeutics-$47.97M-$0.62N/AN/AN/A-36.40%-74.75%-24.25%8/7/2024 (Estimated)PRVBProvention Bio-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/ARTRXTravere Therapeutics-$146.43M-$3.46N/AN/AN/A-49.13%-36.38%-14.90%N/AZIOPZIOPHARM Oncology-$79.98M-$0.43N/AN/AN/AN/A-92.84%-72.46%N/ALatest ZIOP, GTHX, FIXX, RTRX, and PRVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2024Q1 2024GTHXG1 Therapeutics-$0.19-$0.20-$0.01-$0.20$15.21 million$14.48 million 2/28/202412/31/2023GTHXG1 Therapeutics-$0.27-$0.21+$0.06-$0.21$12.83 million$14.87 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFIXXHomology MedicinesN/AN/AN/AN/AN/AGTHXG1 TherapeuticsN/AN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AN/ARTRXTravere TherapeuticsN/AN/AN/AN/AN/AZIOPZIOPHARM OncologyN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFIXXHomology MedicinesN/A7.257.25GTHXG1 Therapeutics1.342.942.55PRVBProvention Bio0.191.931.92RTRXTravere Therapeutics0.667.237.14ZIOPZIOPHARM Oncology0.183.433.43OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFIXXHomology Medicines31.32%GTHXG1 Therapeutics24.21%PRVBProvention Bio37.39%RTRXTravere TherapeuticsN/AZIOPZIOPHARM Oncology51.03%Insider OwnershipCompanyInsider OwnershipFIXXHomology Medicines16.10%GTHXG1 Therapeutics8.23%PRVBProvention Bio13.10%RTRXTravere Therapeutics4.63%ZIOPZIOPHARM Oncology5.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableFIXXHomology Medicines758.13 million48.77 millionOptionableGTHXG1 Therapeutics10052.28 million47.98 millionOptionablePRVBProvention Bio8294.78 million82.37 millionNot OptionableRTRXTravere Therapeutics22151.05 millionN/ANot OptionableZIOPZIOPHARM Oncology105216.15 million204.91 millionOptionableZIOP, GTHX, FIXX, RTRX, and PRVB HeadlinesSourceHeadlineChildhood Cancerscuretoday.com - February 17 at 5:57 PMAlx Oncology Holdings (ALXO)investing.com - February 10 at 8:15 PMPediatric Hematology-Oncology Fellowshipbcm.edu - February 5 at 8:39 AMAlaunos Therapeutics: Other Events, Financial Statements And Exhibitscbonds.com - January 31 at 9:44 AMCG Oncology Increuters.com - January 31 at 4:43 AMOncology Nurses' Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer Patientsmedscape.com - December 21 at 3:43 PMImmuno-Oncologyajmc.com - December 19 at 3:21 PMWhy Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?markets.businessinsider.com - December 18 at 8:18 AMExploring Patient-Centered Handoffs in Surgical Oncologymedscape.com - December 10 at 7:36 PMAssociation of Community Cancer Centersajmc.com - October 14 at 2:50 PMOncology News and Researchnews-medical.net - September 19 at 5:53 PMWBSPH 2024 - Oncologynewsweek.com - September 15 at 8:49 PMKris on Oncologymedscape.com - September 6 at 11:16 PMGauging Ziopharm's Chances for Positive Sarcoma Drug Trial Resultsthestreet.com - August 29 at 6:23 AMOncology Cases & Quizzesmedscape.com - August 14 at 6:15 PMZiopharm’s palifosfamide fails in first-line STS…investing.com - June 21 at 12:05 AMWeber on Oncologymedscape.com - June 19 at 2:11 PMA Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanomaascopubs.org - June 17 at 8:43 AMALX Oncology Holdings Inc Ordinary Sharesmorningstar.com - June 15 at 6:54 PMDivision of Pediatric Hematology and Oncologyslu.edu - June 13 at 3:50 PMDivision of Hematology and Medical Oncologyslu.edu - June 13 at 3:50 PMIntratumoral Cancer Therapies Global Market Report 2023finance.yahoo.com - June 9 at 1:32 PMNatural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.comarketwatch.com - May 11 at 9:52 PMVC Identifies 3 Startups That Will Shake Up the Future of Cancer Caremedcitynews.com - May 10 at 1:58 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsHomology MedicinesNASDAQ:FIXXHomology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.G1 TherapeuticsNASDAQ:GTHXG1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.Provention BioNASDAQ:PRVBProvention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.Travere TherapeuticsNASDAQ:RTRXTravere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.ZIOPHARM OncologyNASDAQ:ZIOPZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.